Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays in the Resistance of Non-small Cell Lung Cancer to Anti-PD1/PD-L1 Therapies

NCT06024538 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT06024538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06024538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays in the Resistance of Non-small Cell Lung Cancer to Anti-PD1/PD-L1 Therapies
Lead sponsor
University Hospital, Bordeaux
Phase
Observational
Overall status
Not yet recruiting
Start date
December 31, 2025
Completion date
December 31, 2026
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer associated fibroblast, lung neoplasm, myeloid-derived suppressive cells immunosuppression